Dapagliflozin Bromomethanone
✓
100% accuracy
of data
24/7 scientific
support
⬡
0% tolerance in
quality of product

Stock Locations

  • New Jersey, USA
  • Czech Republic, EU
  • Mumbai, India

* Stock subject to availability.

Documentation

Download MSDS

Download Sample COA

Includes: HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, Structure Elucidation Report (SER), and additional analytical data depending on the product.

461432-22-4Dapagliflozin Bromomethanone

● In Stock

Catalogue No.:VE006597
CAS No.:461432-22-4
Mol. Formula:C15H12BrClO2
Mol. Weight:339.61 g/mol

Additional information on CAS 461432-22-4

Parent drug

Dapagliflozin

IUPAC Name

(5-bromo-2-chlorophenyl)(4-ethoxyphenyl)methanone

Pharmacopeial Synonyms

N/A

Synonyms

Dapagliflozin Impurity 6; 5-bromo-2-chloro-4′-ethoxybenzophenone

Smiles

O=C(C1=CC(Br)=CC=C1Cl)C2=CC=C(OCC)C=C2

InChI

InChI=1S/C15H12BrClO2/c1-2-19-12-6-3-10(4-7-12)15(18)13-9-11(16)5-8-14(13)17/h3-9H,2H2,1H3

Description

Dapagliflozin Bromomethanone (CAS 461432-22-4), also referred to as Dapagliflozin Impurity 6 or 5-bromo-2-chloro-4'-ethoxybenzophenone, is a process-related halogenated benzophenone impurity monitored in dapagliflozin manufacturing. Its distinct brominated and chlorinated substitution pattern affects chromatographic retention and mass spectral behavior, making it a critical component of impurity profiling, specification setting and stability studies. Identification typically combines HPLC-UV screening with LC-MS confirmation and NMR for structural verification. Effective control relies on validated analytical methods, trace-level quantification, in-process monitoring and suitable sample storage to prevent artifact formation and ensure regulatory compliance.

References

Shao, Hua, et al. “(5-Bromo-2-Chlorophenyl)(4-Ethoxyphenyl)Methanone.” Acta Crystallographica Section E Structure Reports Online, vol. 65, no. 12, Nov. 2009, pp. o3071-71, https://doi.org/10.1107/s1600536809047151.?Plosker, Greg L. “Dapagliflozin: A Review of Its Use in Patients with Type 2 Diabetes.” Drugs, vol. 74, no. 18, Nov. 2014, pp. 2191, 209, https://doi.org/10.1007/s40265-014-0324-3.?

Request a Quote

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
Products quotation
Name
Url